Jul 16, 2020: Keytruda plus chemotherapy reduced the risk of disease progression or death by 35% compared with chemotherapy alone in certain people.

Sep 3, 2020: Researchers reported significant changes in liver, cardiovascular and diabetes markers.

Oct 23, 2020: This association held true for people with or without a history of cancer.

Oct 16, 2020: Researchers found that aggressive Gleason grade group 5 prostate cancer has different subtypes with varying risks.

Aug 31, 2020: The reduction in mortality was most evident during the first 10 years of follow-up after the first scan at age 40.

Sep 10, 2020: Metastatic kidney cancer patients with greater microbial diversity had better outcomes with immunotherapy.

Sep 18, 2020: The treatment method was found to be safe and effective in comparison with surgery or radiation.

Aug 14, 2020: Mailing testing kits to people’s homes lowers costs and increases screening.

Nov 13, 2020: Requiring sobriety prior to treatment and curtailing harm reduction hinder efforts to eliminate hep C.

Aug 24, 2020: Women with early-stage breast cancer showed no upstaging following a postponement of surgery.

Nov 23, 2020: Longer delays were associated with worsening risk of death.

Sep 2, 2020: Liver complications, heart disease and non-liver cancers also account for most deaths among people with hepatitis B or C.

Jul 9, 2020: In contrast, higher plant protein intake was associated with lower incidence of the disease.

Aug 5, 2020: NAFLD is the leading indicator of mortality among Medicare beneficiaries with hepatocellular carcinoma.

Sep 3, 2020: Stivarga also improved survival in those with recurrent HCC after a liver transplant.

Sep 25, 2020: Opdivo and Keytruda are potential alternatives to current first-line therapies.

Jul 24, 2020: Draft recommendation would ensure more women and Black people meet the screening criteria.

Nov 9, 2020: Among patients with high tumor PD-L1 expression, Libtayo lowered mortality by 43%.

Oct 2, 2020: The 30% improvement in survival has brought a Phase III trial to an early halt.

Jul 30, 2020: The program also greatly improved patients’ satisfaction with their hospital stays.